Safety of elevated pulmonary doses from [177Lu]Lu-PSMA-617 and 90Y-radioembolization therapies

被引：0
|
作者：
Jain, S. [1 ]
Graves, S. A. [1 ]
机构：
[1] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-1229
引用
收藏
页码：S919 / S919
页数：1
相关论文
共 50 条
  • [41] BEST PRACTICES IN THE ADMINISTRATION OF [177LU]LU-PSMA-617 RADIOLIGAND THERAPY FOR PROSTATE CANCER IN US CENTERS
    Spitz, Avery
    Gardner, Linda
    Floyd, Rebecca
    Sutton, Jennifer
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [42] Radiation Safety Considerations of Household Waste Disposal After Release of Patients Who Have Received [177Lu]Lu-PSMA-617
    Graves, Stephen A.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (10) : 1567 - 1569
  • [43] Investigation of in vitro models to unravel salivary gland toxicity mechanisms after [177Lu]Lu-PSMA-617 therapy
    Heynickx, N.
    Segers, C.
    Baatout, S.
    Vermeulen, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S426 - S426
  • [44] Effects of [177Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysis
    Soon, Yu Yang
    Marschner, Ian
    Hofman, Michael S.
    Emmett, Louise
    Davis, Ian D.
    Stockler, Martin R.
    Martin, Andrew James
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Quantitative SPECT/CT reconstruction for 177Lu and 177Lu/90Y targeted radionuclide therapies
    Shcherbinin, S.
    Piwowarska-Bilska, H.
    Celler, A.
    Birkenfeld, B.
    PHYSICS IN MEDICINE AND BIOLOGY, 2012, 57 (18): : 5733 - 5747
  • [46] Tumor regression and response of local tumor in mCRPC patients after two cycles of [177Lu]Lu-PSMA-617
    Khreish, F.
    Flach, P.
    Bartholomae, M.
    Maus, S.
    Ezziddin, S.
    Rosar, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S316 - S316
  • [47] Postmarketing safety of [177Lu]Lu-PSMA-617 radioligand therapy for prostate cancer: a disproportionality analysis of the FDA adverse event reporting system
    Zhao, Yan
    Wang, Na
    Zhang, Zhaoqi
    Zhao, Xinming
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [48] Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
    Rosar, Florian
    Krause, Jonas
    Bartholoma, Mark
    Maus, Stephan
    Stemler, Tobias
    Hierlmeier, Ina
    Linxweiler, Johannes
    Ezziddin, Samer
    Khreish, Fadi
    PHARMACEUTICS, 2021, 13 (05)
  • [49] Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis
    Robert Seifert
    Katharina Kessel
    Katrin Schlack
    Matthias Weckesser
    Martin Bögemann
    Kambiz Rahbar
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 2106 - 2112
  • [50] COST-EFFECTIVENESS OF [177LU]LU-PSMA-617 IN PROGRESSIVE PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Brockbank, J.
    Hancock, H.
    Khare, A.
    Joshi, P.
    Risson, V
    VALUE IN HEALTH, 2024, 27 (12) : S121 - S121
12345